Mod­er­na looks past post-Covid 'low point' at a fu­ture based on com­bi­na­tion vac­cines, can­cer in­di­ca­tions

The Covid boom is over at Mod­er­na.

On Thurs­day, the biotech said it was brac­ing for sales to “hit a low point” in 2024 as de­mand wanes for the vac­cine that made it one of the in­dus­try’s biggest suc­cess sto­ries.

While Mod­er­na is stick­ing to its full-year 2023 sales guid­ance of $6 bil­lion to $8 bil­lion, it’s now say­ing that the low end is more re­al­is­tic and sales will be “at least $6 bil­lion.” Rev­enue next year will be around $4 bil­lion, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER